SCHEMBL17690205

SCHEMBL17690205

Cc1cc(C=O)cc(O)c1C

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.46
PTGS2 P35354 1/20 0.46
RAB9A P51151 1/20 0.46
SRC P12931 1/20 0.46
ALDH1A1 P00352 2/20 0.42
AOX1 Q06278 1/20 0.42
XDH P47989 1/20 0.41
TUBB1 Q9H4B7 1/20 0.41
ACHE P22303 1/20 0.39
TRIM24 O15164 1/20 0.38
HPGD P15428 1/20 0.38
ALDH5A1 P51649 1/20 0.38
ABAT P80404 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
TRIM33 Q9UPN9 1/20 0.38
ERN1 O75460 1/20 0.37
CYP3A4 P08684 2/20 0.36
CYP1A2 P05177 1/20 0.36
CYP2D6 P10635 1/20 0.36
CYP2C9 P11712 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3468910 0.88 KDM4E (0.52) KDM4EPTGS2RAB9ASRCALDH1A1
SCHEMBL814444 0.83 SRC (0.48) SRCALDH1A1TUBB1CYP3A4CYP1A2
SCHEMBL299751 0.82 EGFR (0.53) KDM4EPTGS2RAB9ASRCALDH1A1
SCHEMBL29459683 0.82 EGFR (0.53) KDM4EPTGS2RAB9ASRCALDH1A1
SCHEMBL31554021 0.78 KDM4E (0.43) KDM4EPTGS2RAB9ASRCALDH1A1
SCHEMBL12746394 0.78 KDM4E (0.43) KDM4EPTGS2RAB9ASRCALDH1A1
SCHEMBL26856769 0.78 KDM4E (0.43) KDM4EPTGS2RAB9ASRCALDH1A1
SCHEMBL143965 0.78 CYP2C9 (0.56) PTGS2SRCERN1CYP3A4CYP1A2
SCHEMBL11417416 0.77 TUBB1 (0.41) KDM4EPTGS2ALDH1A1TUBB1ACHE
SCHEMBL13271785 0.76 TUBB1 (0.47) PTGS2TUBB1ACHECYP3A4CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230234943-A1 TREX1 INHIBITORS AND USES THEREOF TEMPEST THERAPEUTICS, INC. 2023-07-27 US disclosed
EP-2350030-B9 ISOXAZOLE/ISOXAZOLINE/COMBRETASTATIN LINKED DIHYDROQUINAZOLINONE HYBRIDS AS POTENTIAL ANTICANCER AGENTS AND PROCESS FOR THE PREPARATION THEREOF COUNCIL SCIENT IND RES (IN) 2016-10-26 EP disclosed
EP-2350030-B1 ISOXAZOLE/ISOXAZOLINE/COMBRETASTATIN LINKED DIHYDROQUINAZOLINONE HYBRIDS AS POTENTIAL ANTICANCER AGENTS AND PROCESS FOR THE PREPARATION THEREOF COUNCIL SCIENT IND RES (IN) 2016-04-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230234943-A1 TREX1 INHIBITORS AND USES THEREOF FEN1, ERCC4, DCLRE1B KDM4E 2430/4885PTGS2 2363/4885RAB9A 2016/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.